Immunic presents data from phase 2 emphasis trial of vidofludimus calcium in relapsing-remitting multiple sclerosis at msmilan2023: the 9th joint ectrims-actrims meeting

– improvement in serum neurofilament light chain (nfl) observed in both treatment arms of vidofludimus calcium over placebo – – nfl effect consistent with recently released data from separate, phase 2 calliper trial of vidofludimus calcium in progressive multiple sclerosis – new york , oct. 11, 2023 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that robert j. fox, m.d., staff neurologist, mellen center for multiple sclerosis, vice-chair for research, neurological institute, cleveland clinic, cleveland, ohio, today presented data from the company's phase 2 emphasis trial of nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838), in relapsing-remitting multiple sclerosis (rrms) at msmilan2023: the 9th joint ectrims-actrims meeting, taking place october 11-13 in milan, italy.
IMUX Ratings Summary
IMUX Quant Ranking